GLP-1受体激动剂对肾脏和心血管疾病结局的影响:随机对照试验的荟萃分析
本荟萃分析纳入11项随机对照试验共85373名参与者,评估GLP-1受体激动剂对肾脏和心血管结局的影响。在2型糖尿病患者中,GLP-1受体激动剂较安慰剂降低复合肾脏结局18%、肾衰竭16%、主要不良心血管事件13%及全因死亡12%;严重不良事件无差异,但因不良事件停药更常见。
要点
- 在2型糖尿病患者中,GLP-1受体激动剂降低复合肾脏结局(HR 0.82)、肾衰竭(HR 0.84)、MACE(HR 0.87)和全因死亡(HR 0.88)。
- 纳入SELECT试验后,肾脏和心血管获益相似,与2型糖尿病试验间无显著异质性(p异质性>0.05)。
- 严重不良事件(包括急性胰腺炎和严重低血糖)无差异(RR 0.95),但因不良事件停药更常见(RR 1.51)。
核心结论
- GLP-1受体激动剂显著降低临床重要肾脏事件、肾衰竭和心血管事件。
研究设计与样本
- 本研究为随机对照试验的荟萃分析,检索MEDLINE、Embase和Cochrane Central Register of Controlled Trials自建库至2024年3月26日。
- 纳入标准为至少500名2型糖尿病参与者、比较GLP-1受体激动剂与安慰剂、随访至少12个月并报告主要临床肾脏或心血管结局的随机对照试验。
- 事后纳入SELECT试验(NCT03574597),该试验入组有心血管疾病且BMI≥27 kg/m²的非糖尿病参与者。
- 共纳入11项试验,涉及85373名参与者(29386名女性,55987名男性);其中2型糖尿病参与者67769名。
- 采用随机效应模型分析,研究注册于PROSPERO(CRD42024528864)。
主要发现
- 在2型糖尿病患者中,GLP-1受体激动剂较安慰剂降低复合肾脏结局18%(HR 0.82,95%CI 0.73-0.93;I²=26.41%)。
- 在2型糖尿病患者中,GLP-1受体激动剂较安慰剂降低肾衰竭16%(HR 0.84,95%CI 0.72-0.99;I²=0%)。
- 在2型糖尿病患者中,GLP-1受体激动剂较安慰剂降低MACE 13%(HR 0.87,95%CI 0.81-0.93;I²=49.75%)。
- 在2型糖尿病患者中,GLP-1受体激动剂较安慰剂降低全因死亡12%(HR 0.88,95%CI 0.83-0.93;I²=0%)。
- 纳入SELECT试验后,复合肾脏结局(HR 0.81,95%CI 0.72-0.92;I²=23.11%)、肾衰竭(HR 0.84,95%CI 0.72-0.98;I²=0%)、MACE(HR 0.86,95%CI 0.80-0.92;I²=48.9%)和全因死亡(HR 0.87,95%CI 0.82-0.91;I²=0%)的效应相似,与2型糖尿病试验间无显著异质性(p异质性>0.05)。
关键数值与推荐
- 主要肾脏结局为复合结局:肾衰竭(肾脏替代治疗或持续性eGFR<15 mL/min/1.73 m²)、eGFR持续降低至少50%或最接近等效值、或肾衰竭死亡。
- 主要心血管结局为MACE:心血管死亡、非致死性心肌梗死或非致死性卒中。
- 严重不良事件(包括急性胰腺炎和严重低血糖)在GLP-1受体激动剂组与安慰剂组间无差异(RR 0.95,95%CI 0.90-1.01;I²=88.5%)。
- 因不良事件停药在GLP-1受体激动剂组更常见(RR 1.51,95%CI 1.18-1.94;I²=96.3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials. METHODS: For this meta-analysis, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomised controlled trials that included at least 500 participants with type 2 diabetes, compared a GLP-1 receptor agonist with placebo with at least 12 months of follow-up, and reported a primary clinical kidney or cardiovascular outcome, from database inception to March 26, 2024. Post hoc, we included the SELECT trial (NCT03574597), which enrolled participants with cardiovascular disease and a BMI of 27 kg/m2 or more without diabetes. Study-level summary data were extracted independently by two authors for inclusion in this random-effects analysis. The main kidney outcome was a composite outcome, consisting of kidney failure (kidney replacement therapy or a persistent estimated glomerular filtration rate [eGFR] <15 mL/min per 1·73 m2), a sustained reduction in eGFR by at least 50% or the nearest equivalent, or death from kidney failure. The main cardiovascular outcome was MACE, consisting of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. This study is registered with PROSPERO, CRD42024528864. FINDINGS: Of the 5140 records identified through the literature search, 11 trials, involving 85 373 participants (29 386 female, 55 987 male), were included in the meta-analysis. In participants with type 2 diabetes (67 769), GLP-1 receptor agonists reduced the composite kidney outcome by 18% compared with placebo (hazard ratio [HR] 0·82, 95% CI 0·73-0·93; I2 =26·41%), kidney failure by 16% (HR 0·84, 0·72-0·99; I2 =0%), MACE by 13% (HR 0·87, 0·81-0·93; I2 =49·75%), and all-cause death by 12% (HR 0·88, 0·83-0·93; I2 =0%). The effect on the composite kidney outcome (HR 0·81, 95% CI 0·72-0·92; I2 =23·11%), kidney failure (HR 0·84, 0·72-0·98; I2 =0%), MACE (HR 0·86, 0·80-0·92; I2 =48·9%), and all-cause death (HR 0·87, 0·82-0·91; I2 =0%) was similar when the SELECT trial was included, with no evidence of heterogeneity between this trial and those including participants with type 2 diabetes (pheterogeneity >0·05). There was no difference in the risk of serious adverse events, including acute pancreatitis and severe hypoglycaemia, between the GLP-1 receptor agonist and placebo groups (risk ratio [RR] 0·95, 95% CI 0·90-1·01; I2 =88·5%). However, treatment discontinuation due to adverse events occurred more frequently in the GLP-1 receptor agonist groups (RR 1·51, 95% CI 1·18-1·94; I2 =96·3%). INTERPRETATION: We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events. FUNDING: None.
引用
- Badve SV, Bilal A, Lee MMY, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024. PMID: 39608381. doi:10.1016/S2213-8587(24)00271-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。